The GLP-1 landscape is about to get much more complex. Eli Lilly's retatutride hits three receptors versus the current drugs' one or two and has completed Phase 3 trials. Oral versions are coming. Within five to ten years, there will be many more options targeting specific side effects, muscle preservation, and different administration routes.